RxDoctor Payments Data

Jawad Agha, MD

Internal Medicine · Hazel Park, MINPI 1235164872

Payments from drug & device makers

$3,803in general payments, 2019–2025

Across 221 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$608
  • AbbVie$485
  • Alkermes, Inc.$456
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$445
  • Otsuka America Pharmaceutical, Inc.$377
  • Axsome Therapeutics, Inc.$221
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,803100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,803 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$95,742
Medicare patients
201
Services billed
3,197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide136$178,582
JardianceEmpagliflozin102$140,410
Trelegy ElliptaFluticasone/Umeclidin/Vilanter108$93,903
MounjaroTirzepatide56$58,639
TrulicityDulaglutide41$53,272
Breztri AerosphereBudesonide/Glycopyr/Formoterol47$52,489
FarxigaDapagliflozin Propanediol42$49,520
VraylarCariprazine Hcl24$34,427
EliquisApixaban38$33,244
LinzessLinaclotide25$24,305
Nurtec OdtRimegepant Sulfate17$21,408
XareltoRivaroxaban11$15,368
DuleraMometasone/Formoterol18$8,204
Albuterol Sulfate HfaAlbuterol Sulfate230$7,121
Breo ElliptaFluticasone/Vilanterol16$6,285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$123$178,582136 claims
Boehringer IngelheimJardiance$86$140,410102 claims
Lilly USA, LLCMounjaro, Trulicity$48$111,91097 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$608$107,137111 claims
GSKTrelegy Ellipta, Breo Ellipta$154$100,188124 claims
AbbVieVraylar, Linzess$485$58,73249 claims
PfizerEliquis, Nurtec Odt, Paxlovid$169$56,02267 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Hazel Park

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →